Adding avelumab to cetuximab helps only a specific subgroup of colorectal cancer patients

This research matters for people with metastatic colorectal cancer who are considering treatment options. Many patients have heard about using anti-EGFR drugs like cetuximab after stopping them and starting again. This study looked at whether adding avelumab to that rechallenge strategy would help more people live longer or have their cancer grow slower. The results show that adding avelumab does not increase the overall benefit for the entire group of patients. However, a specific subgroup of patients did see a clear advantage. This finding helps doctors decide who might benefit from this combination therapy and who might not. The researchers studied 156 patients with metastatic colorectal cancer. These patients had the RAS and BRAF wild-type version of the disease. They were randomly assigned to one of two groups. One group received cetuximab plus avelumab. The other group received cetuximab alone. This setup allowed the team to compare the two treatments directly. The main goal was to see how long patients lived, known as overall survival. The secondary goal was to see how long it took for the cancer to grow again, known as progression-free survival. The study followed patients for an average of 5.3 months. The results for the entire group were not significant. The median time without cancer growth was 5.3 months for the combination group and 4.3 months for the group with just cetuximab. The median time patients lived was 14.8 months for the combination group and 12.9 months for the monotherapy group. These differences were not statistically significant for the whole group. The safety profile was not reported in detail in this summary. No specific adverse events or discontinuations were listed in the provided data. The study has important limitations. It was a small trial with only 156 patients. The follow-up time was short at 5.3 months. Because the results were not significant for the whole group, adding avelumab does not increase the efficacy of cetuximab rechallenge for everyone. Patients should not overreact to this single study. This trial is a phase II randomized trial, which is an early stage of testing. It is not a large phase III trial that would change standard practice immediately. The findings suggest that liquid biopsy testing for genomic alterations could help identify patients who benefit. Patients with no genomic alteration, or negative hyperselection, saw significant improvements. Their time without cancer growth was 5.35 months versus 3.65 months. Their survival time was 15.0 months versus 11.1 months. This difference was statistically significant. For patients right now, this means that testing for specific genetic changes might be useful before deciding on treatment. If a patient has those specific changes, they might not benefit from adding avelumab. If they do not have those changes, they might benefit. This supports using the combination therapy for the right people in the continuum of care for metastatic colorectal cancer.